$CLBT

Jewell Marcus sold $7K of CLBT

Jewell Marcus (Global Chief Revenue Officer) sold 411 shares of Cellebrite DI Ltd. (CLBT) at $16.07 on 2026-08-12.

Original reporting
SEC EDGAR · Jewell Marcus
Published Aug 13, 2026, 12:24 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 12:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CLBT
Neutral
high confidence
Mentioned
$CLBT
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLBTNeutralLow
01

Why it matters

The newest fact is the reported open-market sale by the Global Chief Revenue Officer, including share count, price, and post-transaction holdings.

02

Market read

Traders may note insider selling, but the disclosure alone usually does not change valuation without accompanying operational or financial news.

03

What to watch

No 10b5-1 plan is cited, but the article also lacks context on total holdings, prior sales cadence, or whether other insiders sold/bought around the same time.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-13, sale dated 2026-08-12

Background

The article is an SEC Form 4 insider transaction disclosure for Cellebrite DI Ltd. (CLBT).

Company-level read

Ticker impact

$CLBTNeutralHigh confidence
Context

Cellebrite insider Jewell Marcus sold 411 shares at $16.0678 on 2026-08-12, per a newly filed Form 4.

Expected impact

Likely limited near-term impact; any reaction should be small and short-lived unless accompanied by other news.

Evidence & confidence

The filing discloses a specific sale size and price, but provides no new guidance, contracts, litigation, or operational change.

Market effects

No clear sector read-through from a single insider sale.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification or personal liquidity needs and may not reflect bearish views, especially with a small absolute value.

Key entities

  • Cellebrite DI Ltd.

    Subject of the Form 4 insider transaction disclosure.

  • Jewell Marcus

    Global Chief Revenue Officer who sold 411 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.

$CLBTMedAI 8/10

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.